Quick Answer
TANDEM DIABETES CARE INC reported Research And Development Expense of $92.05 million for the year ending 2021.
- TANDEM DIABETES CARE INC showed an increase of +44.8% in Research And Development Expense from 2020 to 2021.
- This data is from TANDEM DIABETES CARE INC's annual report (Form 10-K), filed with the SEC on February 22, 2022.
- XBRL data for this metric is available from 2012 to 2021 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $2.32 million | Q2 2013: $2.76 million | Q3 2013: $2.65 million | Q1 2014: $3.66 million | Q2 2014: $3.70 million | Q3 2014: $4.51 million | Q1 2015: $3.86 million | Q2 2015: $3.87 million | Q3 2015: $5.09 million | Q1 2016: $4.17 million | Q2 2016: $4.14 million | Q3 2016: $6.15 million | Q1 2017: $5.13 million | Q2 2017: $4.87 million | Q3 2017: $4.91 million | Q1 2018: $5.98 million | Q2 2018: $6.46 million | Q3 2018: $8.00 million | Q1 2019: $9.39 million | Q2 2019: $11.20 million | Q3 2019: $12.04 million | Q1 2020: $14.12 million | Q2 2020: $15.99 million | Q3 2020: $16.09 million | Q1 2021: $17.96 million | Q2 2021: $20.50 million | Q3 2021: $24.10 million | Q1 2022: $33.16 million | Q2 2022: $33.57 million.
- Over the full 10 years of available data (2012 to 2021), TANDEM DIABETES CARE INC's Research And Development Expense has grown by 921.8%.
- Historical annual values: Fiscal year 2021: $92.05 million | Fiscal year 2020: $63.57 million | Fiscal year 2019: $45.20 million | Fiscal year 2018: $29.23 million | Fiscal year 2017: $20.66 million | Fiscal year 2016: $18.81 million | Fiscal year 2015: $16.96 million | Fiscal year 2014: $15.79 million | Fiscal year 2013: $11.08 million | Fiscal year 2012: $9.01 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: